Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
Canopus Biopharma, Inc. (OP: CBIA)
0.0260 USD  UNCHANGED
Last Price  /  Updated: 8:10 PM EDT, Mar 13, 2013  /  Add to My Watchlist      
View: Quote News
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 0
Open -
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0260
Today's Range 0.0260 - 0.0260
52wk Range 0.0260 - 0.2600
Shares Outstanding N/A
Dividend Yield N/A
Top News
More News
Fiddler’s Creek in Naples Florida Earns Recognition for “Best Community Newsletter” from the Collier Building Industry Association (CBIA)
November 16, 2012
from Latest Press Releases
Major Influenza Pandemic Threat is now Preventable and Treatable with Canopus’ Aerosol Statin Formulation
May 12, 2009
from Business Wire News Releases

More News
Read More
Working with U.S. Department of Defense, Canopus BioPharma Announces Phase II Human Clinical Trial for Innovative Hepatitis C Drug, CB5300
November 04, 2008
from Business Wire News Releases
Canopus BioPharma Announces Positive Results in Human Study of Novel Peptide Cancer Vaccine
November 03, 2008
from Business Wire News Releases
Canopus Biopharma and Leading Chinese Researcher Team Up to Treat Avian Influenza, to Prevent Possible Pandemic
August 11, 2008
from PR Newswire
CB1400, Patented by Canopus BioPharma, Enters Phase II Clinical Trials for the Prevention of Mucositis in Patients with Cancer of the Head and Neck
June 23, 2008
from Business Wire News Releases
CB1400, Patented by Canopus BioPharma, Enters Phase II Clinical Trials for the Prevention of Mucositis in Patients With Cancer of the Head and Neck
June 23, 2008
from PR Newswire
CB1400, Patented by Canopus BioPharma, Prevents Tumor Growth and Enhances the Anti-Tumor Effects of Cisplatin and Cetuximab (Erbitux)
June 19, 2008
from Business Wire News Releases
CB1400, Patented by Canopus BioPharma, Prevents Tumor Growth and Enhances the Anti-Tumor Effects of Cisplatin and Cetuximab (Erbitux).
June 19, 2008
from PR Newswire
Canopus BioPharma Strengthens its CB1400 Platform Technology for Mucositis and Oncology Treatments Through License Agreement With Wisconsin Alumni Research Foundation
June 18, 2008
from PR Newswire
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here